These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 39261117)

  • 1. Cut-offs for relapse detection in men with stage I testicular germ cell tumors during active surveillance within a prospective multicentre cohort study using either raw or housekeeper normalized miR-371a-3p serum levels.
    Fankhauser CD; Wettstein MS; Christiansen AJ; Rothermundt C; Cathomas R; Kaufmann E; Sigg S; Templeton AJ; Hirschi-Blickenstorfer A; Lorch A; Gillessen S; Beyer J; Hermanns T
    Urol Oncol; 2024 Dec; 42(12):455.e9-455.e13. PubMed ID: 39261117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MiR-371a-3p Serum Levels Are Increased in Recurrence of Testicular Germ Cell Tumor Patients.
    Terbuch A; Adiprasito JB; Stiegelbauer V; Seles M; Klec C; Pichler GP; Resel M; Posch F; Lembeck AL; Stöger H; Szkandera J; Pummer K; Bauernhofer T; Hutterer GC; Gerger A; Stotz M; Pichler M
    Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30321995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. microRNA-371a-3p as informative biomarker for the follow-up of testicular germ cell cancer patients.
    van Agthoven T; Eijkenboom WMH; Looijenga LHJ
    Cell Oncol (Dordr); 2017 Aug; 40(4):379-388. PubMed ID: 28612337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-World Application of Pre-Orchiectomy miR-371a-3p Test in Testicular Germ Cell Tumor Management.
    Badia RR; Abe D; Wong D; Singla N; Savelyeva A; Chertack N; Woldu SL; Lotan Y; Mauck R; Ouyang D; Meng X; Lewis CM; Majmudar K; Jia L; Kapur P; Xu L; Frazier AL; Margulis V; Strand DW; Coleman N; Murray MJ; Amatruda JF; Lafin JT; Bagrodia A
    J Urol; 2021 Jan; 205(1):137-144. PubMed ID: 32856980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of recurrences using serum miR-371a-3p during active surveillance in men with stage I testicular germ cell tumours.
    Fankhauser CD; Christiansen AJ; Rothermundt C; Cathomas R; Wettstein MS; Grossmann NC; Grogg JB; Templeton AJ; Hirschi-Blickenstorfer A; Lorch A; Gillessen S; Moch H; Beyer J; Hermanns T
    Br J Cancer; 2022 May; 126(8):1140-1144. PubMed ID: 34912073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MicroRNA miR-371a-3p in serum of patients with germ cell tumours: evaluations for establishing a serum biomarker.
    Spiekermann M; Belge G; Winter N; Ikogho R; Balks T; Bullerdiek J; Dieckmann KP
    Andrology; 2015 Jan; 3(1):78-84. PubMed ID: 25187505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum Levels of MicroRNA-371a-3p (M371 Test) as a New Biomarker of Testicular Germ Cell Tumors: Results of a Prospective Multicentric Study.
    Dieckmann KP; Radtke A; Geczi L; Matthies C; Anheuser P; Eckardt U; Sommer J; Zengerling F; Trenti E; Pichler R; Belz H; Zastrow S; Winter A; Melchior S; Hammel J; Kranz J; Bolten M; Krege S; Haben B; Loidl W; Ruf CG; Heinzelbecker J; Heidenreich A; Cremers JF; Oing C; Hermanns T; Fankhauser CD; Gillessen S; Reichegger H; Cathomas R; Pichler M; Hentrich M; Eredics K; Lorch A; Wülfing C; Peine S; Wosniok W; Bokemeyer C; Belge G
    J Clin Oncol; 2019 Jun; 37(16):1412-1423. PubMed ID: 30875280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Micro-RNA-371a-3p in Germ Cell Testicular Tumors on Diagnosis: A Prospective Case-Control Study in Turkish Population.
    Kılınç MT; Göger YE; Özkent MS; Kılıç Ö; Okur Altındaş B; Yıldırım MS; Karalezli G
    Urol J; 2024 Jun; 21(4):242-249. PubMed ID: 38629199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utility of Serum miR-371a-3p in Predicting Relapse on Surveillance in Patients with Clinical Stage I Testicular Germ Cell Cancer.
    Lobo J; Leão R; Gillis AJM; van den Berg A; Anson-Cartwright L; Atenafu EG; Kuhathaas K; Chung P; Hansen A; Bedard PL; Jewett MAS; Warde P; O'Malley M; Sweet J; Looijenga LHJ; Hamilton RJ
    Eur Urol Oncol; 2021 Jun; 4(3):483-491. PubMed ID: 33288479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Can germ cell neoplasia in situ be diagnosed by measuring serum levels of microRNA371a-3p?
    Radtke A; Cremers JF; Kliesch S; Riek S; Junker K; Mohamed SA; Anheuser P; Belge G; Dieckmann KP
    J Cancer Res Clin Oncol; 2017 Nov; 143(11):2383-2392. PubMed ID: 28819887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum Levels of MicroRNA miR-371a-3p: A Sensitive and Specific New Biomarker for Germ Cell Tumours.
    Dieckmann KP; Radtke A; Spiekermann M; Balks T; Matthies C; Becker P; Ruf C; Oing C; Oechsle K; Bokemeyer C; Hammel J; Melchior S; Wosniok W; Belge G
    Eur Urol; 2017 Feb; 71(2):213-220. PubMed ID: 27495845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of miR-371a-3p to predict viable germ cell tumor in patients with pure seminoma receiving retroperitoneal lymph node dissection.
    Konneh B; Lafin JT; Howard J; Gerald T; Amini A; Savelyeva A; Woldu SL; Lewis CM; Jia L; Margulis V; Coleman N; Scarpini C; Frazier AL; Murray MJ; Amatruda JF; Bagrodia A
    Andrology; 2023 May; 11(4):634-640. PubMed ID: 36254623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. miR-371a-3p Predicting Viable Tumor in Patients Undergoing Retroperitoneal Lymph Node Dissection for Metastatic Testicular Cancer: The SWENOTECA-MIR Study.
    Thor A; Myklebust MP; Grenabo Bergdahl A; Lundgren PO; Skokic V; Almås B; Haugnes HS; Tandstad T; Akre O; Cohn-Cedermark G; Dahl O; Kjellman A
    J Urol; 2024 Nov; 212(5):720-730. PubMed ID: 39052680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical utility of plasma miR-371a-3p in germ cell tumors.
    Mego M; van Agthoven T; Gronesova P; Chovanec M; Miskovska V; Mardiak J; Looijenga LHJ
    J Cell Mol Med; 2019 Feb; 23(2):1128-1136. PubMed ID: 30536846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A pipeline to quantify serum and cerebrospinal fluid microRNAs for diagnosis and detection of relapse in paediatric malignant germ-cell tumours.
    Murray MJ; Bell E; Raby KL; Rijlaarsdam MA; Gillis AJ; Looijenga LH; Brown H; Destenaves B; Nicholson JC; Coleman N
    Br J Cancer; 2016 Jan; 114(2):151-62. PubMed ID: 26671749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating serum miRNA (miR-367-3p, miR-371a-3p, miR-372-3p and miR-373-3p) as biomarkers in patients with testicular germ cell cancer.
    Syring I; Bartels J; Holdenrieder S; Kristiansen G; Müller SC; Ellinger J
    J Urol; 2015 Jan; 193(1):331-7. PubMed ID: 25046619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicroRNA miR-371a-3p - A Novel Serum Biomarker of Testicular Germ Cell Tumors: Evidence for Specificity from Measurements in Testicular Vein Blood and in Neoplastic Hydrocele Fluid.
    Dieckmann KP; Spiekermann M; Balks T; Ikogho R; Anheuser P; Wosniok W; Loening T; Bullerdiek J; Belge G
    Urol Int; 2016; 97(1):76-83. PubMed ID: 26989896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum Levels of MicroRNA371a-3p: A Highly Sensitive Tool for Diagnosing and Staging Testicular Germ Cell Tumours: A Clinical Case Series.
    Anheuser P; Radtke A; Wülfing C; Kranz J; Belge G; Dieckmann KP
    Urol Int; 2017; 99(1):98-103. PubMed ID: 28586780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum miRNA Predicts Viable Disease after Chemotherapy in Patients with Testicular Nonseminoma Germ Cell Tumor.
    Leão R; van Agthoven T; Figueiredo A; Jewett MAS; Fadaak K; Sweet J; Ahmad AE; Anson-Cartwright L; Chung P; Hansen A; Warde P; Castelo-Branco P; O'Malley M; Bedard PL; Looijenga LHJ; Hamilton RJ
    J Urol; 2018 Jul; 200(1):126-135. PubMed ID: 29474847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of Recurrence through microRNA-371a-3p Serum Levels in a Follow-up of Stage I Testicular Germ Cell Tumors in the DRKS-00019223 Study.
    Belge G; Dumlupinar C; Nestler T; Klemke M; Törzsök P; Trenti E; Pichler R; Loidl W; Che Y; Hiester A; Matthies C; Pichler M; Paffenholz P; Kluth L; Wenzel M; Sommer J; Heinzelbecker J; Schriefer P; Winter A; Zengerling F; Kramer MW; Lengert M; Frey J; Heidenreich A; Wülfing C; Radtke A; Dieckmann KP
    Clin Cancer Res; 2024 Jan; 30(2):404-412. PubMed ID: 37967143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.